- Home
- BWLP vs NVCR Comparison
BWLP vs NVCR Comparison
Compare BWLP & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWLP
- NVCR
- Stock Information
- Founded
- BWLP 1935
- NVCR 2000
- Country
- BWLP Singapore
- NVCR Jersey
- Employees
- BWLP N/A
- NVCR N/A
- Industry
- BWLP Marine Transportation
- NVCR Medical/Dental Instruments
- Sector
- BWLP Consumer Discretionary
- NVCR Health Care
- Exchange
- BWLP Nasdaq
- NVCR Nasdaq
- Market Cap
- BWLP 1.9B
- NVCR 1.8B
- IPO Year
- BWLP N/A
- NVCR 2015
- Fundamental
- Price
- BWLP $12.76
- NVCR $17.49
- Analyst Decision
- BWLP
- NVCR Buy
- Analyst Count
- BWLP 0
- NVCR 5
- Target Price
- BWLP N/A
- NVCR $26.60
- AVG Volume (30 Days)
- BWLP 255.5K
- NVCR 1.3M
- Earning Date
- BWLP 01-01-0001
- NVCR 10-30-2024
- Dividend Yield
- BWLP 24.68%
- NVCR N/A
- EPS Growth
- BWLP 43.64
- NVCR N/A
- EPS
- BWLP 3.64
- NVCR N/A
- Revenue
- BWLP $3,510,244,000.00
- NVCR $549,964,000.00
- Revenue This Year
- BWLP N/A
- NVCR $16.23
- Revenue Next Year
- BWLP N/A
- NVCR $6.09
- P/E Ratio
- BWLP $3.68
- NVCR N/A
- Revenue Growth
- BWLP 57.96
- NVCR 8.33
- 52 Week Low
- BWLP $10.32
- NVCR $10.87
- 52 Week High
- BWLP $22.31
- NVCR $24.74
- Technical
- Relative Strength Index (RSI)
- BWLP 33.59
- NVCR 43.24
- Support Level
- BWLP $13.21
- NVCR $15.61
- Resistance Level
- BWLP $13.58
- NVCR $17.31
- Average True Range (ATR)
- BWLP 0.23
- NVCR 1.29
- MACD
- BWLP -0.15
- NVCR 0.05
- Stochastic Oscillator
- BWLP 2.94
- NVCR 11.59
About BWLP BW LPG Limited Common Shares
BW LPG Ltd is an LPG shipping. It uses pioneering technology to power its vessels with cleaner-burning liquefied petroleum gas (LPG) and invest in R&D to take towards a zero-carbon future. The company is organized into two main segments: The shipping segment and the product services segment which buy and sell liquid petroleum gas and deliver it to customers. It generates the majority of its revenue from the shipping segment.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.